Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.916 USD | -0.42% | -4.07% | -33.87% |
May. 09 | Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating | MT |
May. 09 | Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.87% | 139M | |
+9.74% | 115B | |
+11.91% | 106B | |
-2.50% | 21.96B | |
-13.76% | 21.87B | |
-5.29% | 19.21B | |
-3.39% | 18.08B | |
-38.57% | 17.71B | |
+6.25% | 14.32B | |
+34.55% | 12.42B |
- Stock Market
- Equities
- MCRB Stock
- News Seres Therapeutics, Inc.
- Transcript : Seres Therapeutics, Inc., Q4 2023 Earnings Call, Mar 05, 2024